Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-05-13 | Reverse | 1:30 |
Cardio Diagnostics Holdings, Inc., founded in 2017 in Chicago, develops epigenetics-based clinical tests like Epi+Gen CHD to assess three-year cardiovascular disease risk.

PrecisionCHD™ is an AI-driven blood test that uses genetic and epigenetic biomarkers for early detection and personalized management of coronary heart disease, recently expanding internationally with a launch in India.
| Icon | PRODUCT | Q1-2025 |
|---|---|---|
![]() | Reportable Segments | $940 |
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
BCDA | $1.15 | COMPARE |
NRSN | $0.42 | COMPARE |
BCLI | $1.12 | COMPARE |
ADIL | $5.60 | COMPARE |
ADXN | $3.84 | COMPARE |
TCRT | $1.60 | COMPARE |
RADX | $2.41 | COMPARE |
CELZ | $1.14 | COMPARE |